A.I. Khasanova1,2, Z.F. Gilfanova1, Z.A. Afanasyeva3, A.I. Bilyalov2, S.V. Zinchenko2
1Tatarstan Cancer Center, Kazan
2Kazan (Volga Region) Federal University, Institute of Fundamental Medicine and Biology, Kazan
3Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan
Bilyalov Ayrat I. ― Junior Researcher of Kazan (Volga Region) Federal University, Institute of Fundamental Medicine and Biology
74 Karl Marks Str., Kazan, 420012, Russian Federation, (843) 525-73-82, e-mail BilyalovAir@yandex.ru
The Aim of this article is to present a clinical case of long-term use of the drug Vandetanib, a protein kinase inhibitor, in a patient with disseminated medullary thyroid cancer.
Material and methods. Patient M., 48 years old, has been observed in the Tatarstan Cancer Center since December 2012 with a diagnosis of C.73 ― medullary cancer of the right thyroid lobe.
In December 2012, a right hemithiroidectomy was performed with resection of the isthmus of the thyroid gland. Pathohistological conclusion: Medullary thyroid cancer, tumor invasion into the capsule is not determined, pT2N0M0, stage 2 (TNM 2009).
In May 2014, C83.3 ― diffuse large-B-cell lymphoma (CD30+) was diagnosed. Therapy was performed (6 courses) according to the R-CHOP-Mabter scheme.
In November 2017, according to the RCT of the chest and abdominal organs, multiple liver metastases occurred. Was assigned to therapy with inhibitors of protein kinases
Results. Stabilization of the metastatic process in this patient is 36 months. 30 courses of targeted therapy were conducted. The tolerability of the drug remains satisfactory, there are no adverse events.
Key words: thyroid medullar cancer, Vandetanib, thyroid cancer metastases.